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Class IIa bacteriocins have been primarily explored as natural food preservatives, but there is much interest in exploring the ap-
plicationofthesepeptidesastherapeuticantimicrobialagents.Bacteriocinsofthisclasspossessantimicrobialactivityagainstsever-
al important human pathogens. Therefore, the therapeutic development of these bacteriocins will be reviewed. Biological and
chemical modiﬁcations to both stabilize and increase the potency of bacteriocins are discussed, as well as the optimization of their
production and puriﬁcation. The suitability of bacteriocins as pharmaceuticals is explored through determinations of cytotoxicity,
eﬀects on the natural microbiota, and in vivo eﬃcacy in mouse models. Recent results suggest that class IIa bacteriocins show pro-
mise as a class of therapeutic agents.
1.Introduction
Bacteriocins are natural peptides secreted by many varieties
of bacteria forthe purpose of killing other bacteria. This pro-
vides them with a competitive advantage in their environ-
ment, eliminating competitors to gain resources. These pep-
tides are ribosomally synthesized, although some are exten-
sively posttranslationally modiﬁed.
The classiﬁcation system for bacteriocins has been sub-
ject to ongoing revision [1–3]. However, bacteriocins from
Gram-positive bacteria are generally classiﬁed according to
size,structure,andmodiﬁcations.ClassIbacteriocinsarethe
lantibiotics, which are highly posttranslationally modiﬁed
peptides containing lanthionine and methyllanthionine resi-
dues. Class II consists of small peptides that do not contain
modiﬁed residues. Cotter et al. suggested to divide class II
bacteriocins into several subclasses: class IIa (pediocin-like
bacteriocins), class IIb (two-peptide bacteriocins), and class
IIc (circular bacteriocins) [3]. However, others have suggest-
ed to consider circular bacteriocins as a separate class [4].
Nonbacteriocin lytic proteins, termed bacteriolysins (also re-
ferred to as class III bacteriocins), are large and heat-labile
proteins with a distinct mechanism of action from other
Gram-positive bacteriocins [3].
Class IIa bacteriocins are generally from 37 to 48
amino acids long, and are characterized by several features.
Although they do not have broad spectrum antimicrobial
activity compared to other antibiotics, they are particularly
potent inhibitors of Listeria species, showing activity at low
nanomolar concentrations [5]. They are heat-stable, and not
posttranslationally modiﬁed beyond the proteolytic removal
of a leader peptide and the formation of a conserved N-ter-
minal disulﬁde bridge (although some members contain an
additional C-terminal disulﬁde bridge). The N-terminal re-
gion contains a characteristic YGNGV amino acid sequence,
although variants with the alternate YGNGL sequence have
been classiﬁed in class IIa [6]. A representative class IIa bac-
teriocin is shown in Figure 1. There have been a number of
thorough reviews describing aspects of the genetics, biosyn-
thesis, immunity, structure, mode of action, and the applica-
tion of class IIa bacteriocins to foods [7–13].
Brieﬂy, class IIa bacteriocins kill susceptible bacteria by
formingporesintheirmembranes,resultinginthelossofthe
proton-motive force and depletion of ATP [14]. It is thought
that these cationic bacteriocins are drawn to bacterial cells
through an initial electrostatic interaction [15]. Then, the
amphiphilic C-terminal α-helix inserts into the membrane,
whereinthebacteriocininducestheformationofhydrophilic
pores. This mechanism of action is reliant on a mannose
phosphotransferase (MPT) protein complex found in the
membranes of susceptible organisms, but the exact nature2 International Journal of Microbiology
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Figure 1: A representation of class IIa bacteriocin leucocin A,
with the YGNGV consensus sequence and an N-terminal disulﬁde
bridge.
Figure 2: The NMR solution structure of leucocin A [20].
of this interaction is not yet clear [16–18]. This is covered in
moredetailbyDrideretal.[12]andNissen-Meyeretal.[19].
Structurally, the N-termini of class IIa bacteriocins tend
to exhibit a three-strand antiparallel beta-sheet structure
rigidiﬁed by a disulﬁde bridge. The C-terminal region shows
an amphiphilic helix terminating in a hairpin structure. In
aqueous conditions, class IIa bacteriocins are randomly stru-
ctured. However, membrane-mimicking conditions such as
dodecylphosphocholine micelles or triﬂuoroethanol induce
structure formation [20]. This is not unexpected as their
mode of action involves membrane permeabilization [14].
The NMR solution structures of class IIa bacteriocins leuco-
cin A(shown in Figure 2)[20],carnobacteriocinB2[21]an d
its precursor precarnobacteriocin B2 [22], sakacin P [23],
and curvacin P [24]h a v eb e e ns o l v e dt od a t e .
Much of the research on class IIa bacteriocins has focus-
edontheirapplicationforfoodpreservation.Whiletheymay
be well-suited for this purpose, there is a growing body of
research exploring the prospect of using these bacteriocins as
in vivo therapeutic agents. Bacteriocins are a promising sub-
stitute for conventional antibiotics for several reasons. The
restricted target speciﬁcity of some bacteriocins minimizes
theirimpactoncommensalmicrobiotaandmaydecreasethe
threat of opportunistic pathogens. Furthermore, most bacte-
riocins are active at low concentrations, and their degrada-
tion products are easily metabolized by the body. With the
development of resistance to many important antibiotics,
another tool for ﬁghting bacteria is invaluable.
Class IIa bacteriocins are active against several important
human pathogens. Perhaps most promising is their activity
against the foodborne pathogen Listeria monocytogenes, the
deadliest bacterial source of food poisoning [25]. Up to 30%
of foodborne infections by L. monocytogenes in high-risk in-
dividuals are fatal. Other bacterial foodborne pathogens in-
hibited by some class IIa bacteriocins include Bacillus cereus,
Clostridium botulinum,a n dC. perfringens [5].
Beyond foodborne pathogens, class IIa bacteriocins are
also active against other human pathogens, such as vanco-
mycin-resistant enterococci [26] and the opportunistic path-
ogen Staphylococcus aureus [5]. Although bacteria sensitive
to class IIa bacteriocins are almost exclusively Gram-posi-
tive, the Gram-negative opportunistic pathogen Aeromonas
hydrophila is also inhibited [27]. Bacteriocins from this class
alsoshowotherpotentiallytherapeuticpropertiesasantineo-
plastic [28, 29]a n da n t i v i r a l[ 30] agents.
The potential of other groups of bacteriocins such as lan-
tibiotics, colicins, and microcins as oral and gastrointestinal
antibiotics has been reviewed by Kirkup [31]. Focusing on
bacteriocins from Gram-positive bacteria, there have been
successes with the administration of either lantibiotic-pro-
ducing bacteria [26] or puriﬁed lantibiotics [32–38] for the
treatment of infections by several diﬀerent pathogens. How-
ever, less is known about the in vivo use of class IIa bacterio-
cins.
One method for the therapeutic use of bacteriocins is to
introduce bacteriocinogenic bacteria to the gastrointestinal
tract as probiotics, which has yielded positive results. Fre-
quently, the mechanisms by which probiotic bacteria beneﬁt
the host are not well characterized, but convincing evidence
has been put forth by Corr et al. for the production of class
IIb bacteriocin Abp118 in vivo [39]. Generally, the intro-
duction of bacteriocinogenic bacteria prior to infection with
a pathogen has been more eﬀective [26, 39] than the con-
comitant introduction of both species [40]. This suggests
that probiotic strains may be valuable for prophylactic pur-
poses, but less suited for treating preexisting infections.
Indeed, introduction of a bacteriocin either concomi-
tantly with the infectious agent or postchallenge has proven
eﬀective [32–38]. A variety of administration methods have
been used successfully: subcutaneous, intravenous, intran-
asal, intragastric, intraperitoneal, and topical [41]. The eﬃ-
cacy of the diﬀerent methods has not been directly compared
and likely depends on the pathogen targeted. Furthermore,
some of these methods may be unnecessarily invasive for use
in humans, with oral administration being preferred.
Although the possibility exists of using crude bacteriocin ex-
tract instead of puriﬁed bacteriocin, the introduction of
complex mixtures into a human may be hazardous and less
reproducible. Instead, this paper will focus on the adminis-
tration of puriﬁed class IIa bacteriocin.
ComparedtootherclassesofGram-positivebacteriocins,
the engineering of improved class IIa bacteriocins is some-
what simpliﬁed due to their unmodiﬁed nature. Creating
analogues, by biological or chemical means, does not require
implementationofthethioetherbridgesfoundinlantibiotics
orthecyclizationrequiredforcircularbacteriocins. Nordoes
the recombinant expression of class IIa bacteriocins require
the biosynthetic machinery, such as dehydratases and cyclas-
es, required for some other bacteriocins. This also allows for
the production of class IIa bacteriocins as fusion proteins, a
means of increasing production levels and simplifying puri-
ﬁcations.
This paper will explore diﬀerent aspects of the develop-
ment of class IIa bacteriocins as therapeutic agents for in vivo
utilization. The ﬁrst section discusses attempts to designInternational Journal of Microbiology 3
bacteriocins and bacteriocin analogues with increased sta-
bility and potency. Next, methods for improving production
and puriﬁcation of large amounts of bacteriocin from fer-
mentation and recombinant expression will be explored.
Finally, the suitability of class IIa bacteriocins for therapeutic
use, based on studies testing cytotoxicity, stability, the de-
velopment of resistance, and the in vivo potential of class IIa
bacteriocins will be examined.
2. EngineeringClassIIaBacteriocinsfor
IncreasedStabilityandPotency
The structure-function relationship of class IIa bacteriocins
has been well studied, and its implications for their mode of
action has been well reviewed [8, 12, 19]. This paper focuses
on structure-function as it contributes to the development of
improved therapeutics. Speciﬁcally, engineering bacteriocins
to increase their stability, potency, and spectrum of activity,
such that they are more suitable for in vivo utilization and
other applications will be discussed.
The introduction of an additional disulﬁde bridge likely
hastheeﬀectofrigidifyingaspeciﬁcconformationandcould
resultinimprovedbacteriocinactivity.Thereisasubgroupof
class IIa bacteriocins, including pediocin PA-1, that contain
anadditionaldisulﬁdebridgeneartheC-terminus.Theeﬀect
of introducing a C-terminal disulﬁde bridge into sakacin P,
a bacteriocin containing only the conserved N-terminal di-
sulﬁde bridge, was examined [42]. This modiﬁcation broad-
ened its spectrum of antimicrobial activity in addition to de-
creasing the detrimental eﬀect of increased temperature on
potency. The C-terminus has been otherwise associated with
the target speciﬁcity of class IIa bacteriocins [43]. Notably,
thissakacinPmutantwasfoundtoretainmuchofitsactivity
at 37◦C compared to the natural peptide, and thus is more
eﬀective at human physiological temperature [42].
ThenecessityoftheN-terminaldisulﬁdebridgeforactiv-
ity in class IIa bacteriocins has also been explored. Removal
of this disulﬁde bridge could render bacteriocins more stable
in reductive environments. Substitution of cysteines 9 and 14
of leucocin A [44] and mesentericin Y105 [45] with serines
resulted in a complete loss of activity. However, replacement
with hydrophobic residues such as allylglycine, norvaline,
andphenylalanineresultedinretentionofactivityinleucocin
A[ 46]. Furthermore, the replacement of the disulﬁde bridge
with a carbocycle also yielded a biologically active peptide,
althoughtheactivitywasdecreasedbyanorderofmagnitude
[44]. However, the substitution of cysteines 9 and 14 of ped-
iocin PA-1 with allylglycine and phenylalanine residues re-
sulted in no observable activity [46]. This work has been dis-
cussed further in a mini-review by Sit and Vederas [47].
Class IIa bacteriocins may also be stabilized by simple
amino acid substitutions. Methionine-31 of pediocin PA-1
was found to oxidize over time with an accompanying loss of
activity [48]. Mutation of this residue to leucine, isoleucine
or alanine resulted in only minor decreases in potency while
stabilizing the mutant [48]. Similarly, a 4- to 8-fold decrease
in activity was reported for carnobacteriocin BM1 due to an
oxidized methionine residue [49], but replacement with
a valine residue yielded a mutant with comparable activity
[50]. However, in some cases substitution of only a single
amino acid residue in class IIa bacteriocins results in drama-
tically decreased activity relative to their wild-type counter-
parts [51].
Consideration of the mode of action of class IIa bacterio-
cins may permit the rational design of mutants with increas-
ed potency. Enhancing the net positive charge of a bacterio-
cin may be expected to promote the initial electrostatic inter-
action with the membrane of the target and thus result in
an increase in activity. Support for this was found in the 44K
(withanadditionallysineintroducedtotheC-terminus)and
T20K mutants of sakacin P, which show increased cell bind-
ing and potency relative to the wild-type peptide [52].
Approaches to stabilizing other classes of bacteriocins
may have potential for use with class IIa bacteriocins. Due to
their composition, proteolytic cleavage of bacteriocins in the
gastrointestinal tract represents a major hurdle for any at-
tempts to control gastrointestinal infections. Careful alter-
ation of trypsin recognition sites in class IIb bacteriocin sali-
varicin P had only minor eﬀects on activity [53]. Chemically
synthesized peptides with incorporated d-amino acids may
be similarly expected to render the peptide less susceptible to
proteolytic cleavage. Analogues of class IIb bacteriocin lacto-
coccin G were synthesized with the N- and C-terminal resid-
ues replaced with d-amino acids, which decreased their sus-
ceptibility to exopeptidases without much eﬀect on activity
[54]. However, the extent of incorporation of d-amino acids
has limitations. The enantiomer of leucocin A was synthe-
sized containing exclusively d-amino acids, but it was found
to be largely inactive [55]. This may be rationalized based on
a chiral interaction between class IIa bacteriocins with the
MPT complex [16]. Nonetheless, these methods may be val-
uable for stabilizing class IIa bacteriocins.
Muchworkisfocusedonusingbiologicalmeanstocreate
bacteriocin analogues. Mutagenesis of bacteriocins can be
readily achieved, and large quantities of a desired mutant are
readily available through recombinant expression. However,
the biological production of analogues suﬀers the restriction
oftheproteogenicaminoacidlibrary.Asacontrast,chemical
peptide synthesis oﬀers a vast array of possibilities for the
introduction of nonproteogenic amino acids. Furthermore,
unnatural structural features not found in class IIa bacter-
iocins such as carbocyclic rings and d-amino acids are feasi-
ble. However, chemical peptide synthesis is not trivial, and it
is relatively time consuming and costly. For a chemically syn-
thesized bacteriocin to be considered a viable therapeutic
agent, it would have to be greatly superior to any biologically
producible bacteriocins.
The rational substitution of amino acids in class IIa bac-
teriocinsisonemethodofcreatingmutants,andthishaspro-
vided much information about the structure-function rela-
tionship of these bacteriocins. However, for the most part,
the mutants have had decreased activity relative to the wild-
type bacteriocin. Another common approach uses error-
prone PCR to randomly generate mutants in the hope of
ﬁnding interesting or improved activity. However, approach-
es such as DNA shuﬄing [51] of related bacteriocins and
NNK scanning [56] have been used to randomly generate4 International Journal of Microbiology
vast numbers of mutants, greatly increasing the number
of variants produced without requiring a proportionate
amount of labour.
NNK scanning allows for the systematic examination of
the role of each residue in a peptide. The native codons are
replaced one by one with the NNK triplet oligonucleotide,
replacing the amino acid coded for by that codon with any
of the 20 proteogenic amino acids. This allows for testing a
much larger number of variants without requiring the time
consuming preparation of each mutant separately. Conseq-
uently, the possibility of discovering a mutant with increased
potency is greater. NNK scanning has been applied to pedio-
cin PA-1 to examine the importance of each residue for bac-
tericidal activity and was indeed successful in creating some
mutants with increased activity [56].
Often, changing one amino acid at a time is not suﬃcient
tocreateimprovedvariants.Ithasbeensuggestedthatbacter-
iocins have evolved to be as eﬀective as possible, and so the
creation of improved bacteriocins requires greater modiﬁca-
tion [51]. This is possible using an alternate approach that
allows for the swapping of multiamino acid sequences bet-
ween diﬀerent class IIa bacteriocins to create a hybrid bacter-
iocin.ThisapproachhasbeenusedtocreateaDNA-shuﬄing
library in which regions of pediocin PA-1 have been shuﬄed
with 10 other class IIa bacteriocins [51]. Some of the hybrids
did indeed show increased activity relative to the wild-type
bacteriocins from which they were derived [51].
Another approach explored for creating new analogues
is to mix the N-terminus of one bacteriocin with the C-ter-
minusofanother,therebycreatingachimera.Somechimeras
of pediocin PA-1 with other class IIa bacteriocins showed
eithercomparableor greaterbactericidalactivities tothe cor-
responding natural bacteriocins against certain indicator
strains [43, 51].
These approaches to randomly generate vast numbers of
mutants and hybrids may allow for simpliﬁed drug develop-
ment, facilitating the discovery of novel potent bacteriocins.
Furthermore, these approaches enable the development of
new bacteriocins tailored towards diﬀerent strains of patho-
genic bacteria.
3. Methods for Improving Productionof
ClassIIaBacteriocins
For any potential therapeutic use of class IIa bacteriocins, an
inexpensive method for the production of large quantities
must be available. One possibility is to purify class IIa bacter-
iocins from their natural producer strain, taking advantage
of the cationic and hydrophobic characters of these peptides.
However, these puriﬁcations typically yield only small
amounts of puriﬁed peptide, often consisting of less than a
milligram per liter of culture [49, 57]. However, the outlook
is not bleak, as optimizing culture conditions and improving
the design of puriﬁcations maximizes bacteriocin recovery
and permits increased scale.
Of the class IIa bacteriocins, pediocin PA-1 is most well
characterized in terms of optimization of fermentation. Even
then,reportedyieldsmustbeinterpretedcarefully,asthesen-
sitivity of indicator strains varies and activity tests are per-
formed diﬀerently. A variety of diﬀerent cultivation methods
have been used, such as shake-ﬂasks, batch cultures, and
f e d - b a t c hc u l t u r e s .B a t c hc u l t u r e si nr e a c t o r sg e n e r a l l ya l l o w
for greater control over conditions than shake-ﬂask cultur
es, with precise control of stirring, aeration, and pH. Fed-
batch cultures are similar to batch cultures, except a growth-
limiting nutrient is added over time, allowing for higher cell
densities.
For the large-scale production of class IIa bacteriocins
to be feasible, several conditions must be met. The yield of
the fermentation must be satisfactory, otherwise production
costs will be high. The growth media must also be inexpen-
sive, although this must be balanced with the bacteriocin
yield as the use of more expensive media has been related to
improved bacterial growth and bacteriocin production [58].
The highest reported volumetric productivity was
accomplished by a repeated-cycle batch culture of Pedio-
coccus acidilactici UL5 immobilized in κ-carrageenan/locust
bean gum gel beads, reaching levels of 133mg of pediocin
PA-1 produced per liter per hour in complex de Man
Rogosa and Sharpe (MRS) media [58]. Using less expensive
supplementedwheypermeate(SWP)mediaunderotherwise
identical conditions, 50mg of pediocin PA-1 was produced
per liter per hour. The production of bacteriocins has
tended to be much superior in immobilized cell cultures
compared to free cell cultures [59], as exempliﬁed by the
greater than tenfold increase in production of pediocin PA-1
under immobilized conditions [58]. Naghmouchi et al. have
published an informative literature summary of recent work
on fermentation yields of pediocin PA-1 [58].
Bacteriocin-producing fermentations have been tested
in a large variety of media as an attempt to minimize
productioncosts.Wastefromthefoodindustryespeciallyhas
been investigated as an inexpensive alternative to complex
growth media. Examples of this include mussel-processing
waste [60, 61], whey permeate [58, 62–64], trout and squid
viscera, and swordﬁsh muscle [65]. Complex growth media
tendtobecomposedofamixtureofnutrientstailoredtocer-
tain types of bacteria to meet their speciﬁc nutritional re-
quirements, while industrial eﬄuents are not so optimized
[63, 66].
Although the production of large amounts of bacteriocin
is feasible, the puriﬁcation of these peptides is another
matter. A review by Carolissen-Mackay et al. discusses pre-
vious puriﬁcation approaches for bacteriocins [57]. Many
puriﬁcationprotocolsprovidepooryieldsofbacteriocinwith
recoveriesofunder20%[57].Thesepooryieldsarelikelydue
to unoptimized protocols requiring a large number of steps.
More recently, several general protocols have been published
speciﬁcally for the purpose of purifying class IIa bacteriocins
[67–69]. For the industrial-scale production of bacteriocins
required for therapeutic use, an eﬃcient, inexpensive, and
scalable puriﬁcation scheme with high recovery is needed.
Commonly, the puriﬁcation of class IIa bacteriocins re-
quires precipitation and centrifugation steps. The latter re-
presents a major bottleneck when attempts are made to in-
crease the scale of production. Furthermore, ammoniumInternational Journal of Microbiology 5
sulfate precipitations are frequently a source of loss of mater-
ial, yielding only 40%± 20% for a reported pediocin PA-1
puriﬁcation [67]. Using an initial ion-exchange chromato-
graphic step to concentrate the bacteriocin directly from the
culture media is a possible solution [67].
More recent general puriﬁcation schemes generally fol-
low a similar sequence, taking advantage of the cationic and
hydrophobic character of class IIa bacteriocins. First, the cul-
ture supernatant is passed through a cation-exchange col-
umn [67–69] although loading the whole bacterial culture to
avoid centrifugation has been reported [67]. Following this
step, the eluate is further puriﬁed using hydrophobic inter-
action chromatography, yielding greater than 90% pure bac-
teriocin in only two steps [67, 69]. HPLC may also be used
to further clean up the sample at this stage [68]. These puri-
ﬁcations allow for the acquisition of puriﬁed bacteriocin in
only a few hours [67], with bacteriocin recovery rates report-
ed ranging from 60% [68] to greater than 80% [67].
The development of antibodies capable of recognizing
bacteriocins has allowed for an alternate approach to puriﬁ-
cation, namely, immunoaﬃnity chromatography [70–73].
Indeed, this approach has been used to purify divercin V41,
piscicocin V1b, enterocin P, and pediocin PA-1 from culture
supernatant in a single step. Although reported yields are
sparse, the recovery of enterocin P was 44% [71], while 53%
of pediocin PA-1 was retained [73]. Although pure bacterio-
cin is obtained after a single step, superior yields have been
reported for lengthier procedures [67], and the immuno-
aﬃnity puriﬁcation requires costly noncommercial anti-
body-conjugated resins.
Another notable puriﬁcation approach uses triton X-114
phase partitioning, which has been applied to the puriﬁca-
tion of divercin V41 [74]. This approach does not require re-
moval of bacterial cells from the culture, thereby enabling
collection of the bacteriocin normally lost adhered to the cell
pellet.Afterthetwophasespartition,thedetergentrichphase
is removed, diluted, and loaded on to an ion-exchange col-
umn. Puriﬁed bacteriocin is simply eluted from the column,
with a recovery of greater than 55% [74].
All of these reported puriﬁcations have unique advan-
tages and drawbacks. However, the focus has shifted to the
large-scale production of bacteriocins instead of purifying
only enough for characterization. These approaches have fo-
cusedonattainingimprovedyieldsinfewerstepswithmostly
scalable steps.
3.1.HeterologousExpression. Asanalternativetopuriﬁcation
from the natural producer, the recombinant expression of
bacteriocinsoﬀersapromisingmeansforproducingthelarge
amounts of material required for any potential therapeutic
use. There have been many reports of the heterologous ex-
pression of class IIa bacteriocins in many diﬀerent hosts,
although the focus has been on Gram-positive lactic acid
bacteria phylogenetically similar to the producer strain.
Gram-negative bacteria such as Escherichia coli and yeast ex-
pression platforms such as Saccharomyces cerevisiae have also
been used as expression hosts.
The subject of the heterologous expression of mature
bacteriocins in lactic acid bacteria has been summarized in
an excellent review by Rodr´ ıguez et al. [89], which also dis-
cusses heterologous bacteriocin production in E. coli and
other bacterial strains. Although some of these expression
systems allow for the secretion of active bacteriocin into the
culture supernatant, the quantity of bacteriocin obtained
from these cultures tends to be lower than from the natural
producer strain. As such, this is not yet suitable for the large-
scale production of bacteriocins required for any potential
therapeutic use. However, these heterologous producers may
be suitable for food preservation as many lactic acid bacteria
are generally recognized as safe. Furthermore, these organ-
isms are capable of simultaneously producing multiple dif-
ferent bacteriocins allowing for a greater spectrum of activity
in addition to the possibility of overcoming the development
of resistance [90–92]. However, the use of genetically modi-
ﬁed organisms in food products is still a contentious issue.
The heterologous expression of bacteriocins as fusion
proteins in E. coli has been successfully used for the produc-
tion of larger amounts of bacteriocin than obtained using
other approaches. In particular, the commercial strain E. coli
Origami (DE3) has been used extensively in this area. Muta-
tions in the genes encoding the glutathione and thioredoxin
reductases of this strain allow for the facile formation of the
conserved disulﬁde bridge in the host cytosol.
Additionally,theheterologousexpressionofclassIIabac-
teriocins in E. coli as fusion proteins oﬀers many advantages.
A summary of the reported use of fusion proteins partnered
with class IIa bacteriocins is presented in Table 1. Fusions
with aﬃnity labels, such as hexahistidine tags, allow for
simpliﬁed puriﬁcation protocols. Additionally, some fusion
partnershelpsolubilizethebacteriocinandpreventthedesir-
ed peptide from forming inclusion bodies, allowing for in-
creased bacteriocin production. The presence of a fusion
partner also decreases the antimicrobial activity, avoiding
possible toxic eﬀects on the host cell [93–95], although there
are exceptions [96]. Thioredoxin in particular is useful as
a fusion partner. Beyond circumventing the formation of
inclusion bodies, a thermostable thioredoxin fusion allows
for a thermal coagulation puriﬁcation step [97]. This has
been used to remove high molecular weight contaminants
during the puriﬁcation of carnobacteriocins BM1 and B2
[50]. Furthermore, thioredoxin may even assist in the for-
mation of the conserved N-terminal disulﬁde bridge [97].
Expressionofabacteriocinsolelywithahexahistidinetag
has been reported for pediocin PA-1 [104]. However, this re-
combinant pediocin PA-1 was found to be toxic to the E. coli
producer. The puriﬁcation was complicated by the require-
ment for denaturing conditions to allow for immobilized-
metalaﬃnitychromatography,althoughtheHis-taggedpep-
tide was antimicrobially active. Furthermore, expression of
small-sized recombinant peptides in E. coli is complicated
duetothepresenceofproteases[105].Theexpressionofbac-
teriocins with a larger fusion partner is likely to be advanta-
geous.
The conditions used for fermentations have a signiﬁcant
impact on the amount of fusion protein produced. The ﬁnal
yield of puriﬁed bacteriocin is inﬂuenced by the puriﬁcation
protocol as well as the method used for fusion protein
cleavage. Simple shake-ﬂask cultures have been reported6 International Journal of Microbiology
Table 1: Fusion partners used for class IIa bacteriocins.
Fusion partner Bacteriocin
Thioredoxin
Pediocin PA-1 [95, 98],
carnobacteriocins BM1 and
B2 [50], divercin V41 [96],
enterocin P [72], piscicolin
126 [99]
Maltose-binding protein
Carnobacteriocin B2 [93]
and its precursor [22],
Pediocin AcH [100]
Intein-chitin-binding domain
Piscicolin 126, divercin
V41, enterocin P, pediocin
PA-1 [101]
Dihydrofolate reductase Pediocin PA-1 [94]
Xpress tag Pediocin PA-1 [102]
Cellulose-binding domain Enterocin A [103]
Hexahistidine tag Pediocin PA-1 [104]
most, although many of the reported yields are admittedly
not optimized. Piscicolin 126 was cleaved from a thioredoxin
fusion yielding 26mg per liter [99], while a divercin RV41-
thioredoxin fusion yielded between 18 and 23mg of puriﬁed
peptide per liter of culture [96, 106].
High-cell density E. coli cultures have also been explored
as a means to further increase the production of bacteriocin
fusionproteins[50,106].Thelevelofproductionofarecom-
binant divercin V41-thioredoxin fusion in batch and fed-
batch cultivation has been compared to shake-ﬂask cultures
[106]. Compared to the yield of 18 ± 1mg obtained per liter
in shake ﬂask cultures, batch and fed-batch yielded 30 ± 2
and 74 ± 5mg per liter, respectively. However, the highest
yields reported are for carnobacteriocins BM1 and B2. These
bacteriocins were expressed as thioredoxin fusions in a fed-
batch fermentation induced with lactose. The ﬁnal yields re-
ported are around 320mg of carnobacteriocin BM1 and car-
nobacteriocin B2 per liter of the culture, fourfold greater
than previous reports [50].
A disadvantage of using bacteriocin fusion proteins is the
necessary cleavage and further puriﬁcation required to get
pure bacteriocin. Enzymatic cleavage methods are the most
common approach, while chemical methods have also been
used. Enzymatic approaches oﬀer the advantage of more
speciﬁc recognition sites and are thus more compatible with
most bacteriocin sequences—although the enzyme recogni-
tion is not always infallible [22].
Cyanogenbromide(CNBr)isacommonchemicalmeans
of cleaving fusion proteins, selectively cleaving on the C-ter-
minal side of methionine residues. However, methionine is
found in many class IIa bacteriocins. This has been circum-
vented with carnobacteriocin BM1, wherein methionine-41
was substituted with a valine residue with some impact on
activity [50]. However, CNBr has signiﬁcant advantages over
proteases: cost and cleavage eﬃciency. Besides being much
less expensive, the cleavage eﬃciency of CNBr has been re-
ported to be up to twofold higher than enterokinase [50, 95].
An alternative approach for fusion protein cleavage re-
quires the presence of the amino acid sequence Asp-Pro just
N-terminaltothedesiredsequence.Thiscleavagemethodre-
quires heating under strongly acidic conditions, as has been
applied for the cleavage of a divercin V41 thioredoxin fusion
[106]. This oﬀers an inexpensive method to remove the fu-
sion tag, although these may seem like unsuitable conditions
forapeptide.However,classIIabacteriocinstendtobestable
at elevated temperatures and in acidic conditions [49].
The use of the intein-chitin-binding domain as a fusion
partnerallowsforcircumventionofseveraloftheissuesrelat-
ed to fusion proteins. Following the binding of the fusion
protein on a chitin resin, cleavage is induced with DTT, re-
sulting in elution of puriﬁed bacteriocin without requiring
puriﬁcation from the fusion partner. This has been success-
fully applied for a variety of class IIa bacteriocins, although
the yields have not been very substantial [101].
Yeast expression platforms are another option for the
production of class IIa bacteriocins. Saccharomyces cerevisiae
has been used as an expression host for pediocin PA-1 [107]
and plantaricin 423 [108]. Antimicrobial activity was indeed
observed, and colonies of yeast growing on agar inoculated
with Listeria showed zones of inhibition. However, very little
antimicrobial activity was observed in the supernatant [107,
108]. This low level of activity may be attributed to the bac-
teriocin remaining associated with the fungal cell wall [107].
The use of Pichia pastoris as an expression host is more
promising, showing much higher levels of activity. The levels
of enterocin P produced by P. pastoris r e a c h e dl e v e l su pt o
28mg/L, almost four-fold higher than that produced by the
natural producer strain, Enterococcus faecium P13 [109].
However, the ﬁnal puriﬁed yield of enterocin P from
E. faecium P13 was still superior, demonstrating that im-
proved puriﬁcation methods are required to take advantage
of any increased production. Class IIa-like bacteriocin hira-
cin JM79 has also been expressed in P. pastoris, with similar
issues [91]. Although the quantiﬁed amount of bacteriocin
exceeds that of the natural producer, the observed antimi-
crobial activity was found to be relatively smaller. Neutral
proteases have been suggested as a possible reason for this
discrepancy, and bacteriocin amounts may be overestimated
due to the nature of the quantitative techniques used [91,
109]. Furthermore, the activity of pediocin PA-1 produced
by P. pastoris was found to be inhibited by the presence of
a collagen-like material, which appeared to be covalently
bound to the pediocin [110].
4.In Vivo Utilization of ClassIIaBacteriocins
As previously discussed, most published work regarding the
in vivo use of bacteriocins has focused on the introduction
of probiotic bacteria to the gastrointestinal tract, where they
will potentially secrete bacteriocins. Considerably less re-
search has been done on the administration of puriﬁed bac-
teriocin. The use of probiotic strains may prove beneﬁcial as
aprophylactic,buttheuseofpuriﬁedbacteriocinsappearsto
be superior for countering an established infection. This has
been demonstrated by the administration of either pediocinInternational Journal of Microbiology 7
PA-1 or Pediococcus acidilactici U L 5 ,ap r o d u c e ro fp e d i o c i n
PA-1, to mice infected with L. monocytogenes [40].
An important concern regarding the use of antibiotics is
the eﬀects they have on the microbiota of the body. The pre-
sence of commensal bacteria oﬀers an invaluable barrier to
infection by opportunistic pathogens. Ideally, an antimicro-
bial agent should speciﬁcally target the pathogenic bacteria
with only minimal impact on the natural ﬂora. In fact, the
spectrum of activity for class IIa bacteriocins may be extrem-
ely well suited for targeting speciﬁc pathogens such as L.
monocytogenes in vivo. Pediocin PA-1 has been tested in vitro
against screens of common human intestinal bacteria such as
biﬁdobacteria [75, 76], and at the concentrations tested, no
antagonistic activity was observed against any of the assayed
organisms. This diﬀers from class I lantibiotics nisin A and
nisin Z, both of which inhibited the majority of Gram-posi-
tive strains tested [75, 76]. Similarly, culture supernatant
containing pediocin PA-1 was found to only inhibit one
strain of a screen of common gut bacterial species [77]. Fur-
thermore, an in vivo study of pediocin PA-1 in a mouse
model showed no eﬀect on the composition of the mouse in-
testinal ﬂora. Likewise, puriﬁed pediocin PA-1 fed to rats did
notaﬀectthemajorityoftheirmicrobiota[77].Asacontrast,
antibiotics such as penicillin and tetracycline strongly inhib-
ited most of the common intestinal microbiota tested [76].
Two diﬀerent routes of bacteriocin administration to
ﬁght L. monocytogenes have been tested in mouse models: in-
travenous[78,79]andintragastric[40].Theeﬀectsofpedio-
cin PA-1 have also been studied in uninfected mice [80], rab-
bits [80], and rats [77]. The suitability of the route depends
on the nature of the pathogen being targeted, as well as the
stage of the infection. However, as peptides, bacteriocins face
challenges related to their structure not shared by many anti-
biotics.
Piscicolin 126, recombinant divercin RV41 (DvnRV41),
and structural variants of DvnRV41 were all administered
intravenously to mice previously or soon to be infected with
L.monocytogenes[78,79].Inthecontrol,theintravenousand
intraperitoneal injection of these bacteriocins into healthy
mice resulted in no visible ill eﬀects [78, 79]. The eﬃcacy of
intravenous administration of bacteriocin was tested both
prior to and after the intravenous introduction of Listeria.
Injection of bacteriocins was eﬀective both 15 minutes pre-
challenge and 30 minutes postchallenge. However, adminis-
tration of piscicolin 126 24 hours postchallenge showed no
signiﬁcant reduction in listerial counts. Both of these exper-
iments used only 2μg of puriﬁed bacteriocin. The intracel-
lular nature of Listeria as a pathogen may explain the lack of
sensitivity observed following bacteriocin administration 24
hours postchallenge [25].
A possible concern with the intravenous administration
of peptides is the possibility of an immune response. Foreign
peptides are often antigenic, and the introduction of these
peptides could trigger an immune response. To test this,
pediocin AcH was intraperitoneally introduced into mice
and rabbits to determine its antigenic properties. However,
it did not elicit an antibody response and appears to be
nonimmunogenic [80]. In fact, approaches to develop anti-
bodies to class IIa bacteriocins have required conjugation to
polyacrylamide gel [81] or carrier proteins such as keyhole
limpet hemocyanin [70, 71, 82, 83].
The intragastric administration of bacteriocins suﬀers
from its own set of problems. Bacteriocins are subjected to
harsh environments designed precisely for the proteolytic
cleavage of peptides and proteins. Class IIa bacteriocins are
susceptible to common digestive proteases. Furthermore, the
stomach is a highly acidic environment. However, class IIa
bacteriocins tend to be relatively stable to acidic conditions,
and pediocin PA-1 was stable at pH 2.5 for at least two hours
[84].
The stability of bacteriocins in the gastrointestinal tract
has been examined by passing puriﬁed pediocin PA-1
through an artiﬁcial system mimicking the human stomach
and small intestine [85]. Pediocin PA-1 retained some acti-
vity after 90 minutes in the artiﬁcial gastric conditions, while
allactivitywaslostoncethesamplewasintheduodenalcom-
partment. It was suggested that pancreatin in the duodenum
was responsible for the ultimate cleavage of the pediocin
PA-1, while a combination of pepsin and low pH may be
responsibleforthedecreaseinactivityobservedinthegastric
chamber. This is in agreement with in vivo results, as pedio-
cin PA-1 fed to rats was not detected in their fecal samples
[77].Despitethis,theintragastricadministrationofpediocin
PA-1 has been proven eﬀective for decreasing the load of
L. monocytogenes in a mouse model [40]. Furthermore,
enca-psulation may preserve bacteriocin potency in the
gastrointestinal tract, althoughthis has not been reported for
class IIa bacteriocins as of yet. However, encapsulating the
lantibiotic nisin in liposomes has shown some success [86–
88].
The intragastric administration of pediocin PA-1 to mice
infected with L. monocytogenes has been examined [40].
T r e a t m e n tw i t h2 5 0 μg of pediocin PA-1 a day for three
consecutivedaysresultedin a2-log reductionin fecallisterial
counts. L. monocytogenes generally crosses the epithelial
barrier once it enters the small intestine and then spreads
to the liver, spleen, and central nervous system [25]. This
bacteriocin treatment was found to decrease the amount of
L. monocytogenes reaching the liver and spleen [40].
4.1. Toxicity. An advantage that bacteriocins hold over some
other antimicrobial therapies is their composition. These
peptides can be easily broken down to simple nontoxic
amino acids that are metabolized, although this also means
that they may not be as long-lasting compared to antibiotics.
However, information regarding the in vitro cytotoxicity of
class IIa bacteriocins is relatively limited. The cytotoxicity of
pediocin PA-1 was tested against simian virus 40-transfected
human colon cells and Vero monkey kidney cells [111]. At
the levels tested, pediocin PA-1 did show cytotoxic eﬀects
on both cell lines, with a bacteriocin dose of 700AU/mL
(likely around 10–20mg/mL) causing a decrease of greater
than 50% on the viable cell counts. Lower dosages also
aﬀected the viable cell count, although this was not as
dramatic. However, combinations of carnobacteriocins BM1
and B2 at concentrations 100-fold higher than required
for antimicrobial activity displayed no signiﬁcant cytotoxic8 International Journal of Microbiology
eﬀects to the human gastrointestinal Caco-2 cell line [112].
The means of bacteriocin production and puriﬁcation must
also be considered with respect to potential toxic eﬀects.
Although this paper focuses on the administration of
puriﬁed bacteriocin only, there still may be the possibility of
toxiccontaminantsretainedinthebacteriocinsample,which
could confuse any toxicity results obtained.
Based on the diﬀering results obtained from these two
in vitro studies, further work must be done to carefully
examine what amounts of class IIa bacteriocins can be used
safely without cytotoxic eﬀects. However, it is promising that
mouse and rabbit models did not show detrimental eﬀects
from bacteriocin introduction [40, 79, 80].
4.2. Resistance Mechanisms. As with all therapeutic antibi-
otics, the development of resistance to class IIa bacteriocins
in pathogenic bacteria is a critical issue to consider. This
topic has been the subject of a recent review by Kaur et
al. [113]. Much evidence has shown that the sensitivity
of a bacterial strain to class IIa bacteriocins is dependent
on the presence of a mannose phosphotransferase (MPT)
transporter system [16, 114–116]. Additionally, there is
evidence that nonclass IIa bacteriocin lactococcin A also
requires MPT as a receptor [17]. Decreased expression levels
of MPT have been implicated in resistance to class IIa
bacteriocins in many strains of L. monocytogenes insensitive
to bacteriocins [114].
Beyond decreased receptor expression, L. monocytogenes
and other susceptible strains have developed other resistance
mechanisms. Multiple mechanisms may be operative at once
contributingtoanoverallresistantphenotype.Modiﬁcations
of the bacterial membrane have been implicated as another
source of bacterial resistance. Alterations of the bacterial
membrane, such that the acyl chains of phosphotidylglyc-
erols are shorter and more unsaturated, aﬀect membrane
ﬂuidity and the eﬃciency of bacteriocin insertion [117, 118].
Several other observed cell surface adaptations have been
implicated in resistance, such as increasing the net positive
charge on the membrane and lysinylation of membrane
phospholipids [119].
Of special concern is the cross-resistance that has been
observedforbacteriocinsfromdiﬀerentclasses.Forexample,
as t r a i no fL. monocytogenes has shown resistance to nisin,
pediocin PA-1, and leuconocin S, bacteriocins from three
separate classes [120]. Based on this, the prospect of using
multiple bacteriocins to overcome resistant strains may not
be entirely feasible. Like other antibiotics, bacteriocins need
to be used judiciously to minimize the spread of resistant
phenotypes.
5. Conclusions
Class IIa bacteriocins are antagonistic to many important
human pathogens. These bacteriocins have the ability to
target a relatively narrow range of bacteria without aﬀecting
much of the natural microbiota of the body, which is an
important advantage, especially when compared to other
antibiotics. Although these bacteriocins do not target as
many pathogens as other antibiotics, they have the potential
to perform a very speciﬁc role. Having another tool to
combat infections is especially important with consideration
of the ever-growing problem of antibiotic resistance.
Although relatively little has been published about the
actual in vivo use of class IIa bacteriocins to control bacter-
ial infections, what is known is promising. Preliminary ex-
periments have shown these bacteriocins to be eﬀective at
ﬁghting L. monocytogenes infections in mouse models.
Now, more is known about the mode of action of bac-
teriocins, and attempts at engineering bacteriocins with
greaterpotencyandstabilityhavebeensuccessful.Compared
tosomeotherclassesofbacteriocins,classIIabacteriocinsare
especially suitable for facile recombinant production and the
preparationofanalogues.Improvedfermentationconditions
in combination with scalable eﬃcient puriﬁcations are now
known, allowing for the industrial-scale production of pure
bacteriocin. The recombinant production of class IIa bacte-
riocins as a variety of fusion proteins in E. coli has also been
successful, allowing for the production of even greater
amounts of bacteriocin.
The application of class IIa bacteriocins as therapeutic
agents is a rapidly developing area, and there is still much
to investigate. In particular, determination of their eﬃcacy
againstpathogensotherthanL.monocytogenesisopenforex-
ploration and would further reveal their potential for thera-
peutic use. In addition, it would be informative to test these
bacteriocins against a wider range of targets beyond Gram-
positive bacteria, as they have displayed unexpected activity.
The methodology is now in place to produce and purify
large amounts of class IIa bacteriocins. The preliminary
characterization that has been done reveals that this class of
bacteriocins possesses several desirable and useful properties
as in vivo antimicrobial agents. What remains now is to use
that knowledge to fully explore the suitability of these pep-
tides as in vivo antibiotics.
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